Are Analysts Bullish about NuVasive, Inc. (NASDAQ:NUVA) after last week?

April 16, 2018 - By Clifton Ray

NuVasive, Inc. (NASDAQ:NUVA) LogoInvestors sentiment decreased to 0.91 in Q4 2017. Its down 0.04, from 0.95 in 2017Q3. It fall, as 39 investors sold NuVasive, Inc. shares while 78 reduced holdings. 37 funds opened positions while 70 raised stakes. 51.31 million shares or 4.77% less from 53.88 million shares in 2017Q3 were reported.
Lombard Odier Asset (Switzerland) holds 120,000 shares. Bnp Paribas Arbitrage Sa reported 23,004 shares. Amalgamated Comml Bank has invested 0.01% in NuVasive, Inc. (NASDAQ:NUVA). Voya Inv Mngmt Limited Liability Company, Georgia-based fund reported 755,294 shares. Gabelli Funds Limited Co accumulated 360,263 shares. Fort Washington Advisors Oh stated it has 0.16% in NuVasive, Inc. (NASDAQ:NUVA). Capital holds 0.04% or 2.43M shares in its portfolio. Norris Perne And French Ltd Liability Partnership Mi has 157,988 shares for 1.34% of their portfolio. Sg Americas Secs Limited Liability Co holds 0.01% or 16,846 shares in its portfolio. Metropolitan Life accumulated 29,065 shares. Guggenheim Ltd stated it has 0% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA). Regions Financial holds 0% in NuVasive, Inc. (NASDAQ:NUVA) or 689 shares. 5,550 are owned by Rathbone Brothers Public Ltd. Cwm Lc holds 200 shares or 0% of its portfolio. Teacher Retirement Systems Of Texas holds 0.01% or 17,393 shares in its portfolio.

Since March 1, 2018, it had 2 insider purchases, and 0 sales for $593,220 activity.

NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage

Among 13 analysts covering NuVasive (NASDAQ:NUVA), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. NuVasive had 19 analyst reports since October 19, 2017 according to SRatingsIntel. The company was maintained on Tuesday, February 27 by Leerink Swann. The rating was downgraded by Leerink Swann on Thursday, February 1 to “Market Perform”. The firm earned “Buy” rating on Monday, February 26 by Jefferies. The firm has “Outperform” rating given on Wednesday, October 25 by BMO Capital Markets. The stock of NuVasive, Inc. (NASDAQ:NUVA) has “Buy” rating given on Friday, November 10 by RBC Capital Markets. The rating was maintained by Barclays Capital with “Overweight” on Tuesday, February 27. The stock of NuVasive, Inc. (NASDAQ:NUVA) has “Market Perform” rating given on Wednesday, January 17 by Wells Fargo. On Thursday, October 19 the stock rating was maintained by Barclays Capital with “Overweight”. The stock of NuVasive, Inc. (NASDAQ:NUVA) earned “Buy” rating by Canaccord Genuity on Tuesday, February 27. Canaccord Genuity maintained the shares of NUVA in report on Monday, October 23 with “Buy” rating. Below is a list of NuVasive, Inc. (NASDAQ:NUVA) latest ratings and price target changes.

04/04/2018 Broker: Goldman Sachs Rating: Neutral New Target: $47 Initiates Coverage On
27/02/2018 Broker: Robert W. Baird Rating: Hold New Target: $55.0 Maintain
27/02/2018 Broker: Cowen & Co Rating: Buy New Target: $62.0 Maintain
26/02/2018 Broker: Jefferies Rating: Buy New Target: $57.0 Maintain
27/02/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $66 New Target: $62 Maintain
27/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $67 New Target: $55 Maintain
27/02/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $51 New Target: $52 Maintain
27/02/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $81 New Target: $73 Maintain
01/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Downgrade
17/01/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Old Target: $65 Downgrade

The stock decreased 0.04% or $0.02 during the last trading session, reaching $54.99. About 422,322 shares traded. NuVasive, Inc. (NASDAQ:NUVA) has declined 32.39% since April 16, 2017 and is downtrending. It has underperformed by 43.94% the S&P500.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. The company has market cap of $2.82 billion. The Company’s products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. It has a 36.66 P/E ratio. The companyÂ’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

NuVasive, Inc. (NASDAQ:NUVA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: